دورية أكاديمية
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study
| العنوان: | Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study |
|---|---|
| المؤلفون: | Costanzo A., Russo F., Galluzzo M., Stingeni L., Scuderi R., Zichichi L., Papini M., Di Costanzo L., Conti A., Burlando M., Chiricozzi A., Gaiani F. M., Mugheddu C., Musumeci M. L., Gisondi P., Piaserico S., Dapavo P., Venturini M., Pagnanelli G., Amerio P., Potenza C., Peris K., Cantoresi F., Trevisini S., Loconsole F., Offidani A., Mercuri S. R., Lora V., Prignano F., Bartezaghi M., Oliva G., Aloisi E., Orsenigo R. |
| المساهمون: | Costanzo, A, Russo, F, Galluzzo, M, Stingeni, L, Scuderi, R, Zichichi, L, Papini, M, Di Costanzo, L, Conti, A, Burlando, M, Chiricozzi, A, Gaiani, Fm, Mugheddu, C, Musumeci, Ml, Gisondi, P, Piaserico, S, Dapavo, P, Venturini, M, Pagnanelli, G, Amerio, P, Potenza, C, Peris, K, Cantoresi, F, Trevisini, S, Loconsole, F, Offidani, A, Mercuri, Sr, Lora, V, Prignano, F, Bartezaghi, M, Oliva, G, Aloisi, E, Orsenigo, R |
| بيانات النشر: | ACTA DERMATO-VENEREOLOGICA |
| سنة النشر: | 2021 |
| المجموعة: | Universitá degli Studi di Roma "Tor Vergata": ART - Archivio Istituzionale della Ricerca |
| مصطلحات موضوعية: | interleukin-17A, psoriasis, PASI 90, secukinumab, Antibodies, Monoclonal, Humanized, Humans, Severity of Illness Index, Treatment Outcome, Settore MED/35 - MALATTIE CUTANEE E VENEREE |
| الوصف: | Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/33903916; info:eu-repo/semantics/altIdentifier/wos/WOS:000729250900001; volume:101; issue:10; firstpage:adv00576; journal:ACTA DERMATO-VENEREOLOGICA; http://hdl.handle.net/2108/284056Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85115646749 |
| DOI: | 10.2340/00015555-3816 |
| الإتاحة: | https://doi.org/10.2340/00015555-3816Test http://hdl.handle.net/2108/284056Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.9FF16D59 |
| قاعدة البيانات: | BASE |
| DOI: | 10.2340/00015555-3816 |
|---|